| Primary |
| Drug Eruption |
12.9% |
| Prophylaxis |
12.9% |
| Ovarian Cancer |
9.7% |
| Hiv Infection |
6.5% |
| Hypercholesterolaemia |
6.5% |
| Lyme Disease |
6.5% |
| Pruritus |
6.5% |
| Rash |
6.5% |
| Antiemetic Supportive Care |
3.2% |
| Asthma |
3.2% |
| Bipolar Disorder |
3.2% |
| Breast Cancer |
3.2% |
| Hypersensitivity |
3.2% |
| Inflammatory Bowel Disease |
3.2% |
| Nasopharyngitis |
3.2% |
| Off Label Use |
3.2% |
| Rhinitis Allergic |
3.2% |
| Sedation |
3.2% |
|
| Liver Disorder |
9.5% |
| Rash |
9.5% |
| Fatigue |
4.8% |
| Hepatic Enzyme Abnormal |
4.8% |
| Leukaemia |
4.8% |
| Off Label Use |
4.8% |
| Oropharyngeal Pain |
4.8% |
| Palpitations |
4.8% |
| Somnolence |
4.8% |
| Staphylococcal Sepsis |
4.8% |
| Streptococcus Test Positive |
4.8% |
| Tachycardia |
4.8% |
| Throat Irritation |
4.8% |
| Tinnitus |
4.8% |
| Tooth Disorder |
4.8% |
| Tremor |
4.8% |
| Urinary Retention |
4.8% |
| Urticaria |
4.8% |
| White Blood Cell Count Decreased |
4.8% |
|
| Secondary |
| Product Used For Unknown Indication |
17.8% |
| Drug Use For Unknown Indication |
11.9% |
| Nasopharyngitis |
11.0% |
| Prophylaxis |
10.2% |
| Nausea |
5.9% |
| Hiv Infection |
5.1% |
| Asthma |
4.2% |
| Urticaria Chronic |
4.2% |
| Borderline Personality Disorder |
3.4% |
| Cervix Carcinoma |
3.4% |
| Depression |
3.4% |
| Otitis Media Acute |
3.4% |
| Vomiting |
3.4% |
| Hypersensitivity |
2.5% |
| Bipolar Disorder |
1.7% |
| Constipation |
1.7% |
| Genital Neoplasm Malignant Female |
1.7% |
| Hypercholesterolaemia |
1.7% |
| Ovarian Cancer |
1.7% |
| Rash |
1.7% |
|
| Premature Baby |
13.0% |
| Drug Exposure During Pregnancy |
8.7% |
| Pyrexia |
8.7% |
| Tachycardia |
8.7% |
| Type I Hypersensitivity |
8.7% |
| Blood Creatine Phosphokinase Increased |
4.3% |
| Cardio-respiratory Arrest |
4.3% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.3% |
| Gingival Bleeding |
4.3% |
| Oropharyngeal Pain |
4.3% |
| Polyneuropathy |
4.3% |
| Rash Generalised |
4.3% |
| Somnolence |
4.3% |
| Syncope |
4.3% |
| Tremor |
4.3% |
| Urticaria |
4.3% |
| Vomiting |
4.3% |
|
| Concomitant |
| Drug Use For Unknown Indication |
19.0% |
| Product Used For Unknown Indication |
16.7% |
| Prophylaxis |
14.6% |
| Premedication |
9.9% |
| Asthma |
6.6% |
| Hypertension |
5.7% |
| Rash |
3.3% |
| Chronic Lymphocytic Leukaemia |
2.8% |
| Non-hodgkin's Lymphoma |
2.6% |
| Germ Cell Cancer |
2.3% |
| Influenza |
2.3% |
| Insomnia |
2.0% |
| Nausea |
2.0% |
| Chronic Hepatitis C |
1.9% |
| Glioblastoma Multiforme |
1.9% |
| Diarrhoea |
1.3% |
| Diffuse Large B-cell Lymphoma |
1.3% |
| Pain |
1.3% |
| Prophylaxis Of Nausea And Vomiting |
1.3% |
| Diabetes Mellitus |
1.2% |
|
| Pyrexia |
9.1% |
| Vomiting |
7.3% |
| Weight Decreased |
7.3% |
| Pruritus |
6.4% |
| Intention Tremor |
5.5% |
| Jaundice |
5.5% |
| Pneumonia |
5.5% |
| Abnormal Behaviour |
4.5% |
| Death |
4.5% |
| Infusion Related Reaction |
4.5% |
| Thrombocytopenia |
4.5% |
| Toxic Skin Eruption |
4.5% |
| Urticaria |
4.5% |
| White Blood Cell Count Decreased |
4.5% |
| Hepatic Enzyme Increased |
3.6% |
| Lung Disorder |
3.6% |
| Pancytopenia |
3.6% |
| Priapism |
3.6% |
| Urinary Tract Infection |
3.6% |
| Vulvovaginal Dryness |
3.6% |
|
